B of A Securities Rates Tyra Biosciences (TYRA) buy
B of A Securities reaffirms its buy rating on TYRA Biosciences with a price target of $42.00, as the stock trades at $26.99, a 55.61% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
B of A Securities rated Tyra Biosciences, Inc. ($TYRA) "buy" with a $42 price target on June 10, 2026.
Since the rating, $TYRA is up 14.4% after 1 week, up 28.8% after 1 month and down 27.1% to date (from the $25.42 close on Jun 10, 2026).
TYRA
Tyra Biosciences, Inc.
Key Points
- On June 10, 2026, B of A Securities reiterated its buy rating on TYRA Biosciences, setting a price target of $42.00, while the stock closed at $26.99.
- B of A Securities's $42 price target implies 55.61% upside from Tyra Biosciences, Inc.'s ($TYRA) current $26.99 share price.
- The average price target among analysts for TYRA is $48.30, with a consensus rating of 'strong buy' from 10 analysts.
- In the latest quarter, TYRA reported no earnings, but has a market capitalization of approximately $1.76 billion.
Get $TYRA trade alerts by text
We text you when insiders, Congress or big funds trade $TYRA. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Tyra Biosciences, Inc. alert may contain errors. Disclosures
Analysts Set New Price Targets
On June 10, 2026, B of A Securities reiterated its buy rating on TYRA Biosciences, Inc. (NasdaqGS: TYRA) with a price target of $42.00. The stock closed at $26.99 that day, reflecting a strong outlook from the firm.
What This Means for TYRA
B of A's reaffirmation indicates confidence in TYRA's growth potential. The company has been developing precision medicines targeting fibroblast growth factor receptor (FGFR) biology. Its lead candidate, currently in clinical trials, aims to treat metastatic urothelial carcinoma. The price target suggests significant upside potential from the current trading levels.
Analysts Set New Price Targets
Several other analysts have also recently commented on TYRA. On September 10, 2026, Wedbush reiterated an 'Outperform' rating with a target of $53.00. Earlier, on the same day, HC Wainwright & Co. maintained its 'Buy' rating but lowered its target to $30.00 from $45.00. Oppenheimer also reiterated its 'Outperform' rating with a revised target of $40.00, down from $50.00. The mean price target across all analysts stands at $48.30, indicating a strong buy consensus among 10 analysts.
How TYRA Stock Has Traded
Currently trading at $26.99, TYRA is well below its52-week high of $40.65. The stock has faced volatility but shows potential for recovery, especially with the recent analyst support. The current price is above its 50-day moving average of $27.60, suggesting some stability in the short term.
$TYRA price target
Tyra Biosciences, Inc. daily closes and this analyst's $42 target. Not advice.
What TYRA Does
Tyra Biosciences, Inc. is a clinical-stage biotechnology firm based in Carlsbad, California. The company focuses on developing innovative therapies for various oncology and genetic conditions. Its pipeline also includes treatments for skeletal conditions and other serious diseases. The recent analyst support aligns with its strategic push in these areas.
What’s Next for TYRA
Investors will be watching closely as TYRA prepares for its next earnings report on November 4, 2026. The upcoming results could provide further insights into the company's progress and market position. Additionally, the recent 13F filings will be worth reviewing to understand institutional ownership trends as they may reflect confidence in the company’s future prospects.
Related Filing Alerts
Source: B of A Securities's rating change on $TYRA (Jun 10, 2026). Written by software, not financial advice. How we make alerts